Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Common Equity (2016 - 2026)

Cumberland Pharmaceuticals' Common Equity history spans 16 years, with the latest figure at $24.5 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 7.4% to $24.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.5 million, a 7.4% increase, with the full-year FY2025 number at $24.5 million, up 7.4% from a year prior.
  • Common Equity hit $24.5 million in Q4 2025 for Cumberland Pharmaceuticals, down from $26.1 million in the prior quarter.
  • Over the last five years, Common Equity for CPIX hit a ceiling of $47.8 million in Q2 2021 and a floor of $22.9 million in Q4 2024.
  • Historically, Common Equity has averaged $34.2 million across 5 years, with a median of $35.8 million in 2022.
  • Biggest five-year swings in Common Equity: plummeted 31.37% in 2024 and later grew 7.4% in 2025.
  • Tracing CPIX's Common Equity over 5 years: stood at $42.6 million in 2021, then decreased by 15.56% to $36.0 million in 2022, then dropped by 18.66% to $29.3 million in 2023, then fell by 21.89% to $22.9 million in 2024, then rose by 7.4% to $24.5 million in 2025.
  • Business Quant data shows Common Equity for CPIX at $24.5 million in Q4 2025, $26.1 million in Q3 2025, and $27.7 million in Q2 2025.